Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant milestones.</li><li>Consolidated enterprise results showcased a 10% increase in total revenue to $54.8 billion, primarily fueled by the Pharma segment.</li><li>Despite flat revenue of $3.8 billion in the Medical segment, the company exceeded expectations in Q1.</li></ul>

Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant milestones.Consolidated enterprise results showcased a 10% increase in total revenue to $54.8 billion, primarily fueled by the Pharma segment.Despite flat revenue of $3.8 billion in the Medical segment, the company exceeded expectations in Q1.

Cardinal Health: The Powerhouse Behind Today’s Medical and Pharmaceutical Breakthroughs! - Major Drivers

<ul><li>Cardinal Health Inc. delivered a positive result and managed an all-around beat last quarter.</li><li>The Pharma segment demonstrated remarkable profit growth of 13%, and the company generated significant adjusted free cash flow amounting to $2.8 billion.</li><li>Cardinal Health pursued determined actions to advance its strategic imperatives, streamlining its operations, optimizing its organizational structure, and instituting fundamental leadership changes.</li></ul>

Cardinal Health Inc. delivered a positive result and managed an all-around beat last quarter.The Pharma segment demonstrated remarkable profit growth of 13%, and the company generated significant adjusted free cash flow amounting to $2.8 billion.Cardinal Health pursued determined actions to advance its strategic imperatives, streamlining its operations, optimizing its organizational structure, and instituting fundamental leadership changes.

Cardinal Health Inc.: How Their Pioneering NTrainer System 2.0 is Changing Neonatal Care Forever! - Major Drivers

<ul><li>It was a successful Q3 2023 for Cardinal Health, with a solid overall performance and an all-around beat.</li><li>The Pharma business demonstrated resilience and growth, benefiting from its critical role in the pharmaceutical supply chain and a solid customer base.</li><li>Cardinal Health is working towards to inflation mitigation and growth initiatives to achieve its target of at least $650 million in segment profit by fiscal 2025.</li></ul>

It was a successful Q3 2023 for Cardinal Health, with a solid overall performance and an all-around beat.The Pharma business demonstrated resilience and growth, benefiting from its critical role in the pharmaceutical supply chain and a solid customer base.Cardinal Health is working towards to inflation mitigation and growth initiatives to achieve its target of at least $650 million in segment profit by fiscal 2025.

Cardinal Health Inc.: Collaboration With Signify Health & Other Drivers

<ul><li>Cardinal Health, one of the largest wholesalers of the healthcare industry in the U.S., continued its strong performance in the last quarter and managed to deliver an all-around beat.</li><li>Cardinal Health’s total revenue has increased by 13% in the last quarter, and the gross margin increased by 3%, driven by the Pharma segment.</li><li>There was an increasing overall pharmaceutical demand and a strong performance from the Generics programs.</li></ul>

Cardinal Health, one of the largest wholesalers of the healthcare industry in the U.S., continued its strong performance in the last quarter and managed to deliver an all-around beat.Cardinal Health’s total revenue has increased by 13% in the last quarter, and the gross margin increased by 3%, driven by the Pharma segment.There was an increasing overall pharmaceutical demand and a strong performance from the Generics programs.

Credit

<ul><li>Cardinal Health is one of the largest wholesalers within the healthcare domain in the U.S.</li><li>The company’s recent financial performance has been fairly decent, largely driven by its Pharma segment growth despite managing industry-wide inflationary headwinds.</li><li>Upstream and Specialty, the company’s third-party logistics business, has been continuing its strong growth new launches.</li></ul>

Cardinal Health is one of the largest wholesalers within the healthcare domain in the U.S.The company’s recent financial performance has been fairly decent, largely driven by its Pharma segment growth despite managing industry-wide inflationary headwinds.Upstream and Specialty, the company’s third-party logistics business, has been continuing its strong growth new launches.

Cardinal Health Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

United States

Cardinal Health, Inc. provides complementary products and services to healthcare providers and manufacturers.  The Company's services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cardinal Health (CAH US)

Cardinal Health: The Powerhouse Behind Today’s Medical and Pharmaceutical Breakthroughs! - Major Drivers

Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant...

Baptista Research

Cardinal Health Inc.: How Their Pioneering NTrainer System 2.0 is Changing Neonatal Care Forever! - Major Drivers

Cardinal Health Inc. delivered a positive result and managed an all-around beat last quarter. The Pharma segment demonstrated remarkable profit...

Baptista Research

Cardinal Health Inc.: Collaboration With Signify Health & Other Drivers

It was a successful Q3 2023 for Cardinal Health, with a solid overall performance and an all-around beat. The Pharma business demonstrated...

Baptista Research

Cardinal Health Inc: Major Drivers

Cardinal Health, one of the largest wholesalers of the healthcare industry in the U.S., continued its strong performance in the last quarter and...

Baptista Research

Cardinal Health Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

Cardinal Health is one of the largest wholesalers within the healthcare domain in the U.S. The company’s recent financial performance has been...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)